Hot Features
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company’s lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (... Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company’s lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.1909 | 9.4039408867 | 2.03 | 2.29 | 2.015 | 3840778 | 2.12504068 | CS |
| 4 | 0.1509 | 7.28985507246 | 2.07 | 2.29 | 1.88 | 3573809 | 2.0600896 | CS |
| 12 | -3.0991 | -58.2537593985 | 5.32 | 6.845 | 1.5 | 8383614 | 2.19196724 | CS |
| 26 | -3.1391 | -58.5652985075 | 5.36 | 6.88 | 1.5 | 5061881 | 2.99485674 | CS |
| 52 | -0.3291 | -12.9058823529 | 2.55 | 6.88 | 1.5 | 3276665 | 3.24551058 | CS |
| 156 | -0.9591 | -30.1603773585 | 3.18 | 6.88 | 0.765 | 1535216 | 2.8881682 | CS |
| 260 | -1.8791 | -45.8317073171 | 4.1 | 6.88 | 0.765 | 1037422 | 2.91487945 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.